Human Liver Sinusoidal Microvascular Endothelial Cells

Human liver sinusoidal microvascular endothelial cells (LSECs) are a specialized endothelial population lining the hepatic sinusoids, distinguished by the presence of transcellular fenestrations, the absence of a organized basement membrane, and a unique repertoire of scavenger receptors (e.g., Stabilin‑1/-2, LRP‑1, mannose receptor). These fenestrated, sieve‑like structures enable bidirectional passage of solutes and macromolecules between sinusoidal blood and hepatocytes, making LSECs central to liver metabolic regulation, lipid trafficking, and waste clearance.

Compared to vascular endothelial cells from large vessels (e.g., HUVEC), primary human LSECs offer several unique advantages for research and pharmaceutical applications:

1. High endocytic clearance capacity - LSECs are the body's most efficient scavenger cells, contributing to >70 % of total liver clearance of soluble macromolecules, waste products (e.g., hyaluronic acid, AGEs), and modified plasma proteins. This property is essential for drug delivery studies and evaluation of nanoparticle‑based therapies.
2. Immune‑privileged and tolerogenic functions - LSECs express PD‑L1, scavenging receptors, and cross‑present MHC I, inducing regulatory T cells and peripheral tolerance. They are therefore a powerful tool for modeling hepatic immune regulation and chronic inflammation.
3. Direct involvement in fibrosis and portal hypertension - Upon activation, LSECs undergo capillarization, a critical step in fibrogenesis. Primary LSECs allow exact mechanistic studies of sinusoidal remodeling and drug screening for anti‑fibrotic strategies.
4. Physiologically relevant drug metabolism and toxicity models - Co‑cultured with hepatocytes, LSECs recreate the native liver microenvironment, improving prediction of drug‑induced liver injury (DILI) and metabolism.